Mounjaro vs Saxenda: Two Generations Apart

Mounjaro (tirzepatide, Eli Lilly) vs Saxenda (liraglutide, Novo Nordisk)

Last verified November 2026

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The verdict

Tirzepatide weekly against liraglutide daily. Mounjaro reported −7% to −12% across the SURPASS diabetes trials and, as Zepbound, −20.9% in SURMOUNT-1; Saxenda reported −8.0% at 56 weeks in SCALE Obesity. Both list at well over $1,000 a month, so for a cash payer the realistic comparison is not these two but Zepbound's LillyDirect pricing ($299–$449), or the compounded market below.

Side-by-side comparison

Mounjaro vs Saxenda, side by side
FieldMounjaroSaxenda
FDA-approved indicationType 2 diabetes mellitus (adults)Chronic weight management (adults BMI ≥30 or ≥27 + comorbidity; pediatric 12+ ≥60 kg)
ManufacturerEli LillyNovo Nordisk
How it worksHits two receptors, GIP and GLP-1Hits one, GLP-1
How often you injectOnce a week, under the skinEvery day, under the skin
How long it stays in youAbout five daysAbout 13 hours
Weight lost-7% to -12% in the diabetes trials; the same molecule under its weight brand reached -20.9% over 72 weeks-8.0% over 56 weeks (SCALE Obesity)
Whether a trial proved it prevents heart attacks and strokesSURPASS-CVOT (2025): noninferior to dulaglutide (HR 0.92); MACE indication on the labelLEADER cut major cardiac events 13% — at the 1.8 mg diabetes dose, not this 3.0 mg one
What it costs if you pay cash$499/mo via LillyDirect self-pay at every strengthAbout $1,349/mo retail, with no manufacturer cash program at all
Youngest approved ageNot approved for children12 and over, at 60 kg or more, with a BMI matching the adult obesity threshold

What each one costs in the compounded market

Standing monthly cash prices from the 734 sellers on this register. These are compounded preparations, not the approved products compared above.

Mounjaro — tirzepatide

from $69 /mo

453 sellers publish a standing price. This is the lowest of all 453; the median is $228.28 a month.

Where to get tirzepatide — a selection of sellers, not a price ranking

Saxenda — liraglutide

from $149 /mo

5 sellers publish a standing price. This is the lowest of all 5; the median is $160 a month.

Where to get liraglutide — a selection of sellers, not a price ranking

⚠ A compounded preparation is not the approved product. No agency has reviewed that specific preparation for safety, effectiveness or manufacturing quality, and the legal ground under compounding these molecules narrowed when the shortages closed. The price gap is real, and so is the difference in oversight. Every seller, with its price record.

Frequently asked questions

Are Mounjaro and Saxenda the same drug?

No. Mounjaro is tirzepatide and Saxenda is liraglutide — different molecules. Results with one do not predict results with the other.

Is Mounjaro or Saxenda cheaper?

On the manufacturers' own cash pricing: Mounjaro at $499/mo via LillyDirect self-pay at every strength, Saxenda at About $1,349/mo retail, with no manufacturer cash program at all. That is the list-price comparison, and it is not what most people pay. What you actually pay depends on whether your plan covers it, which formulary tier it sits in, and whether you have met your deductible — and for many people the honest comparison is between an insured copay and a cash-pay compounded alternative rather than between these two figures.

What does a compounded version of each actually cost?

Across the 734 sellers in this register, the cheapest standing monthly cash prices we hold are tirzepatide from $69 a month and liraglutide from $149 a month. A compounded preparation is not the approved product: no agency has reviewed that specific preparation for safety, effectiveness or manufacturing quality, and the legal ground under compounding these molecules narrowed once the shortages closed. The price gap is real and so is the difference in oversight.

Can I switch from Mounjaro to Saxenda?

Yes, with a prescriber. Expect to re-titrate from the bottom of the new drug's ladder rather than starting where you left off: these are different molecules and tolerance to one does not transfer to the other. Both the old drug's washout and the new drug's schedule apply.

Which one should I ask for?

That is a prescriber's call, and anyone answering it from a table is guessing. What a page like this can do is tell you what the trials measured, what the manufacturers charge, and where the evidence is still missing, so the conversation starts from the record rather than from an advertisement.

References

  1. 1.Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes). N Engl J Med. 2015. PMID: 26132939.
  2. 2.Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021. PMID: 34170647.
  3. 3.Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). N Engl J Med. 2016. PMID: 27295427.
  4. 4.Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. PMID: 35658024.
  5. 5.Eli Lilly and Company. MOUNJARO (tirzepatide) injection — FDA prescribing information. DailyMed (NIH/NLM). 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
  6. 6.Novo Nordisk. SAXENDA (liraglutide) injection — FDA prescribing information. DailyMed (NIH/NLM). 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143
  7. 7.Eli Lilly and Company. Mounjaro savings card eligibility — commercially insured patients with type 2 diabetes. LillyDirect. 2026. https://www.lillydirect.lilly.com/pharmacy/mounjaro
  8. 8.Nicholls SJ, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes N Engl J Med. 2025. PMID: 41406444.

See the full drug-vs-drug verdict index or provider rankings.